Bladder and Ureter Cancer Drug Development Pipeline Review, 2017 [Report Updated: 22122017] Prices from USD $3995
Bladder and Ureter Cancer Drug Development Pipeline Review, 2017
Summary
This report provides an overview of the bladder and ureter pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for these two indications, and features dormant and discontinued projects.
Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. There are a total of 223 products in development for this indication, by 158 companies and 19 academic institutions. Key companies active in this space include F. HoffmannLa Roche, GlaxoSmithKline, AstraZeneca, MedImmune and Pfizer.
Ureter or ureteral cancer affects the ureter, the tube that transports urine from the kidney to the urinary bladder. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. This pipeline is far smaller; there are a total of nine products in development for this indication, by six companies and two academic institutions.
Scope
Which companies are the most active within each pipeline?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important RD milestones and data publications to have happened in this disease area?
Reasons to buy
Understand the overall pipeline, with an ataglance overview of all products in therapeutic development for each indication
Assess the products in development in granular detail, with an uptodate overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Original Article: Bladder and Ureter Cancer Drug Development Pipeline Review, 2017 [Report Updated: 22122017] Prices from USD $3995
